Metabolic and inflammatory mechanisms contribute to the development of MASH,2,3 with insulin resistance playing a significant role in the pathogenesis of the disease, as reflected by a reduced hepatic, whole body, and adipose tissue insulin sensitivity in this patient population.4 The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.